STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #504 by analyst upside · 2026-06-27
MOLN
Molecular Partners AG
Healthcare · Market Cap $143M · P/E 0x
ANALYST PRICE TARGET
+183.8%
implied upside to consensus target
Current Price $3.8
Consensus Target $10.79
Bull Target $16.43
Bear Target $3.65
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
1
Sell
0
52-Week Low $3.41
52-Week High $5.36
YTD Return -10.0%
FUNDAMENTALS
Market Cap $143M
P/E Ratio (TTM) N/A
Forward P/E -14.3x
EPS (TTM) $-1.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.41
52-Week High $5.36
Current Price $3.8
Bear Target $3.65
Bull Target $16.43
● Now $3.8 ● Target $10.79
TRADING DATA
Avg Volume 5K
YTD Return -10.0%
Analyst Count 5
Consensus Buy
Upside to Target +183.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Molecular Partners AG (MOLN) is currently trading at $3.8 with a Wall Street consensus price target of $10.79, implying potential upside of 183.8% over the next 12 months. 5 analysts currently cover MOLN, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.43, while the most cautious has a target of $3.65.

MOLN operates in the Healthcare sector with a market capitalisation of $143M. The stock is down 10.0% year-to-date and is currently trading near the lower end of its 52-week range of $3.41 – $5.36.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MOLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-04-22 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-16 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-01-27 31% win rate (48 calls)
JP Morgan — Reiterated
Neutral → Neutral 2025-12-08 43% win rate (7 calls)
JP Morgan — Reiterated
Neutral → Neutral 2025-09-03 43% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-03-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →